1621513-95-8Relevant articles and documents
NOVEL COMPOUND HAVING ISOXAZOLE CORE AND PHARMACEUTICAL COMPOSITION FOR DIABETES CONTAINING THE SAME MOLECULAR SKELETONS
-
Paragraph 0077; 0088-0090, (2017/08/02)
The purpose of the present invention is to provide novel compounds having isoxazole by central structure as a PPAR gamma selective ligand, a manufacturing method thereof, and a pharmaceutical composition for treating PPAR gamma-related diseases containing the novel compounds or pharmaceutically acceptable salt thereof. The compounds can be applied to treatment of PPAR gamma-related diseases, especially, diabetes as an effective medicine without side effects which an existing TZD-series diabetes medicine has.